I spent four crazy years writing about Cassava Sciences, Adam Feuerstein writes. Yesterday, the story ended exactly as many ...

Nestled in a prime location, this exceptional 5 bedroom house offers the perfect blend of spacious living and entrepreneurial potential. The property boasts a conveniently situated shop at the back, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fair Park Middle School is a public school located in Shreveport, LA, which is in a mid-size city setting. The student population of Fair Park Middle School is 611 and the school serves 6-8.

Caddo Middle Career and Technology School is a public school located in Shreveport, LA, which is in a mid-size city setting. The student population of Caddo Middle Career and Technology School is ...

Barclays raised the firm’s price target on Sarepta (SRPT) to $209 from $203 and keeps an Overweight rating on the shares. The company reported a big Q3 beat on both total and Elevidys revenue ...

Cantor Fitzgerald analyst Kristen Kluska upgraded Sarepta (SRPT) to Overweight from Neutral with a price target of $167, up from $152. The company reported Q3 earnings, the first full quarter ...

(RTTNews) - Below are the earnings highlights for Sarepta Therapeutics (SRPT): Earnings: $33.6 million in Q3 vs. -$40.9 million in the same period last year. EPS: $0.34 in Q3 vs. -$0.46 in the ...

Sarepta Therapeutics (SRPT) reported $467.17 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 40.8%. EPS of $0.62 for the same period compares to ...

A new patient group is being enrolled in a Phase 1/2 trial of delpacibart braxlosiran (del-brax), an experimental and potentially disease-modifying therapy for facioscapulohumeral muscular dystrophy ...

Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ...